Anti-CD19 chimeric antigen receptor T cell therapy - iCarTAB Biomed

Next Previous
Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - iCarTAB Biomed

Alternative Names: Anti-CD19-CAR-T cells - iCarTAB Biomed

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iCarTAB BioMed
  • Developer iCarTAB BioMed; Nanjing University
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cell replacements; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Leukaemia; Lymphoma

Most Recent Events

  • 23 Oct 2017 Phase-I clinical trials in Leukaemia (Recurrent, Second-line therapy or greater) in China (IV) (ChiCTR-OIC-17013081)
  • 23 Oct 2017 Phase-I clinical trials in Lymphoma (Recurrent, Second-line therapy or greater) in China (IV) (ChiCTR-OIC-17013081)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top